Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Catalent announced the launch of the ProteoSuiteSM Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into clinical trials.
read more
Piramal Pharma Solutions announced the completion of an integrated development and manufacturing of drug substance and drug product for Brenzavvy™ (bexagliflozin), TheracosBio’s recently approved treatment for type 2 diabetes.
read more
Vantage Nutrition, an ACG company announces full shareholding ownership of ComboCap Inc (USA) and BioCap (South Africa).
read more
The global clinical trials outsourcing market size is expected to reach $67.62B by 2030, according to a Research & Markets study.
read more
The global Omega-3 market–which grew from ~$2B in 2017, estimated to ~US$3B by 2022–is forecasted to grow further into ~$4B by 2028, owing to the increasing demand for supplement products from the pharmaceutical sector, growing health concerns among consumers, and health and skincare benefits, according to a report by Research & Markets.
read more
The companion animal pharmaceutical market revenue was estimated at $14.4B in 2022 and is poised to reach $19.6B by 2027, growing at a CAGR of 6.3% from 2022 to 2027, according to a report by MarketsandMarkets™.
read more
The empty capsules industry was estimated to be worth $3.2B in 2023 and is poised to reach $4.9B by 2028, growing at a CAGR of 9.3% from 2023 to 2028, according to a new report by MarketsandMarkets™.
read more
Hovione and Laxxon Medical announced a strategic collaboration to advance the use of 3D screen printing technologies for the pharmaceutical industry. This partnership combines Laxxon´s expertise in 3D screen printing, based on their SPID®-Technology, with Hovione's product & process development, engineering and manufacturing expertise in ...
read more
The probiotic dietary supplements market size will grow from $6.4B in 2022 to $6.8Bin 2023 at a compound annual growth rate (CAGR) of more than 7%. The probiotic dietary supplements market size is then expected to grow to $9.4B in 2027 at a CAGR of more than 8%, according to a report from the Business Research Company.
read more
Pfizer announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to ...
read more
The global generic pharmaceuticals market is expected to grow from $302.39B in 2021 to $332.43B in 2022 at a compound annual growth rate (CAGR) of 9.9%, according to a report from Research & Markets. The generic pharmaceuticals market is expected to reach $426.30 billion in 2026 at a CAGR of 6.4%.
read more
The global brain health supplements market, estimated at $ 8B in 2022, is projected to reach $15B by 2028 growing at a CAGR of ~10% during 2022-2028, according to a study by Research & Markets.
read more
ABVC Biopharma, a clinical stage biopharmaceutical company announced that BioKey, a wholly-owned subsidiary based in Fremont, California, received an approval of Maitake Mushroom Dietary Supplement Tablet from Taiwan Ministry of Health and Welfare (MHW).
read more
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and NATCO Pharma Limited announced the launch of additional strengths for the generic version of Revlimid® (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the U.S.
read more
Accord Healthcare, a generic pharmaceutical company, has added Teriflunomide to its portfolio of oral medications. The drug is formulated as a film-coated tablet. Accord's Teriflunomide is therapeutically equivalent to Sanofi Genzyme's Aubagio® and is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically ...
read more